Scarica l'app Stockscreener
2.33
0.85%
-0.02
Dopo l'orario di chiusura:
2.33
Precedente Chiudi:
$2.35
Aprire:
$2.35
Volume 24 ore:
303.95K
Relative Volume:
0.51
Capitalizzazione di mercato:
$208.62M
Reddito:
-
Utile/perdita netta:
$1.60M
Rapporto P/E:
77.67
EPS:
0.03
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
-4.12%
1M Prestazione:
+52.29%
6M Prestazione:
+31.64%
1 anno Prestazione:
-3.32%
Intervallo 1D:
$2.3001
$2.38
Intervallo di 1 settimana:
$2.24
$2.41
Portata 52W:
$1.35
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
Confronta CGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.33 | 208.62M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Iniziato | Oppenheimer | Outperform |
| 2022-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-26 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-05-13 | Iniziato | Stifel | Buy |
| 2020-05-07 | Iniziato | SVB Leerink | Outperform |
| 2020-04-22 | Iniziato | ROTH Capital | Buy |
| 2020-03-24 | Iniziato | SunTrust | Buy |
| 2020-01-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Iniziato | Oppenheimer | Outperform |
| 2016-02-01 | Ripresa | Oppenheimer | Outperform |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2015-04-23 | Ripresa | Jefferies | Buy |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-02-07 | Iniziato | MLV & Co | Buy |
| 2009-12-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2009-07-29 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Compugen Ltd Borsa (CGEN) Ultime notizie
Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving AverageTime to Sell? - MarketBeat
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - Simply Wall St
Compugen (NASDAQ:CGEN) Now Covered by Oppenheimer - Defense World
Compugen Ltd (NASDAQ: CGEN) Gains 3.14% In Early Trade; What Lies Ahead? - Stocks Register
Oppenheimer Initiates Coverage on Compugen (NASDAQ:CGEN) - MarketBeat
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential By Investing.com - Investing.com Australia
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential - Investing.com India
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - Marketscreener.com
Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 - StockTitan
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy - AOL
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail
3 Penny Stocks With 10% to 210% Upside Potential - The Globe and Mail
Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks
Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada
Compugen Reports Strong Q3 2024 Results and Progress - TipRanks
Compugen: Q3 Earnings Snapshot - The Washington Post
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance
Compugen earnings beat by $0.11, revenue topped estimates - Investing.com India
Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compugen Surges with $17.1M Revenue, Reports Breakthrough Cancer Drug Progress - StockTitan
Compugen to Participate in Stifel 2024 Healthcare Conference - StockTitan
Compugen (CGEN) to Release Quarterly Earnings on Tuesday - Defense World
Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year - Simply Wall St
Compugen Showcases Promising Data on Ovarian Cancer Therapy - TipRanks
Compugen's Cancer Drug Combo Shows 17.4% Response Rate in Ovarian Cancer Trial | CGEN Stock News - StockTitan
Short Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1% - MarketBeat
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - cnhinews.com
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Compugen Ltd Azioni (CGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):